中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

5987 records (took 0.071 seconds)

    Detection of anthrax pathogenicity factors
    122.
    发明专利
    Detection of anthrax pathogenicity factors 未知

    公开(公告)号：AU2007254461B2

    公开(公告)日：2013-01-17

    申请号：AU2007254461

    申请日：2007-02-15

    Applicant: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY

    Inventor： BARR JOHN R ,  BOYER ANNE E ,  QUINN CONRAD P

    IPC: C12Q1/00 ,  C12N9/00 ,  G01N33/569

    Abstract: One major problem in diagnosis methods presently available for anthrax is that these methods require several days to produce a result. The only existing treatment for anthrax requires administration soon after infection at a time when patients are exhibiting only mild flu- like symptoms. Thus, a patient may be days beyond the time when treatment would be effective by the time a diagnosis is made. The present invention reduces diagnosis time to as little as four hours providing same day identification of anthrax radically increasing the odds of delivering proper treatment and patient recovery. The rapid identification of anthrax lethal factor activity exhibited by the instant invention is also amenable to in vivo screening protocols for the discovery and development of anthrax vaccines and lethal factor inhibitors. The instant invention isolates and concentrates lethal factor and lethal toxin from nearly any biological sample. By capitalizing on the endopeptidase activity of lethal factor the present invention amplifies output signals producing reliable detection of picomolar concentrations of lethal factor. The instant invention involves novel purification and detection techniques and substrates for rapid, reproducible, and quantitative measurements of anthrax lethal factor in biological samples.

    Inhibition of HIV infection through chemoprophylaxis
    123.
    发明专利
    Inhibition of HIV infection through chemoprophylaxis 未知

    公开(公告)号：AU2007212583B2

    公开(公告)日：2012-12-06

    申请号：AU2007212583

    申请日：2007-02-01

    Applicant: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH

    Inventor： GARCIA-LERMA J GERARDO ,  FOLKS THOMAS ,  OTTEN RONALD ,  JANSSEN ROBERT ,  HENEINE WALID

    IPC: A61K31/52 ,  A61K31/505 ,  A61K31/675 ,  A61P31/18

    Abstract: A process is provided for protecting a primate host from a self-replicating infection by an immunodeficiency retrovirus. Protection is achieved by administering to the primate host a combination of a pharmaceutically effective amount of a nucleoside reverse transcriptase inhibitor and a pharmaceutically effective amount of a nucleotide reverse transcriptase inhibitor prior to exposure to the immunodeficiency retrovirus. The administration is effective if provided in a single dose within 24 hours of the exposure. A regime of regular daily doses is also effective in providing protection against an immunodeficiency retrovirus becoming self- replicating after infecting a primate host. A process for controlling retrovirus transmission within a population includes the administration to a subpopulation at high risk for contracting an immunodeficiency retroviral infection the detailed combination prior to sexual exposure to a source of immunodeficiency retrovirus so as to preclude the immunodeficiency retrovirus from becoming self-replicating in a member of the subpopulation.

    Compositions and methods for modulating RSV infection and immunity
    126.
    发明专利
    Compositions and methods for modulating RSV infection and immunity 未知

    公开(公告)号：AU2009200997B2

    公开(公告)日：2011-12-22

    申请号：AU2009200997

    申请日：2009-03-12

    Applicant: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY

    Inventor： ANDERSON LARRY J ,  LES JONES ,  TRIPP RALPH A

    IPC: C07K14/135 ,  A61K38/00 ,  A61K39/00

    Abstract: Compositions and methods are provided for the treatment or prevention of RSV disease by modulating RSV infection and immunity. In particular, amino acid sequences in the RSV G glycoprotein, containing the chemokine motif defined as C-X-X-X-C (or CX3C), are identified that are essential in causing RSV infection and disease. The chemokine motif is biologically active and participates in virus binding to and infection of susceptible cells. The prevention or treatment of RSV infection is achieved by interfering with the motif, such as by administering a vaccine in which the motif is altered or by administration or induction of blocking molecules that inhibit the biological activity of the motif. 293-CX3CR1 + FKN 293 + FKN FIG.1A FIG. 1B 293-CX3CR1 + G 293 + G FIG. 1C FIG.1D 293-CX3CR1 + G 293-CX3CR1 + G + RT32 + RT34 +RT33 FIG. 1E FIG. 1F

    Peptide vaccines against group A streptococci
    128.
    发明专利
    Peptide vaccines against group A streptococci 未知

    公开(公告)号：AU2008203277B2

    公开(公告)日：2011-07-07

    申请号：AU2008203277

    申请日：2008-07-23

    Applicant: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY

    Inventor： ADES EDWIN W ,  BEALL BERNARD W ,  SAMPSON JACQUELYN S ,  CARLONE GEORGE M

    IPC: C07K14/315 ,  A61K39/00 ,  A61K39/02 ,  A61K39/09 ,  C12N1/21

    Abstract: This invention, in one aspect, relates to synthetic immunoreactive peptides. These peptides are approximately 20-25 amino acids in length which are portions of the N termini of the M proteins of the most prevalent United States (U.S) Group A Streptococcus (GAS) serotypes. At least some of the synthetic peptides can be recognized by M type-specific antibodies and are capable of eliciting functional opsonic antibodies andlor anti-attachment antibodies without eliciting tissue cross-reactive antibodies. In another aspect, it relates to compositions or vaccines comprising these synthetic serotype-specific peptides, including polypeptides and proteins. This invention may also be isolated antibodies which are raised in response to the peptides, compositions or vaccines. The invention further relates to kits for using the peptides, compositions, or antibodies. In still further aspects, the invention also relates to methods for using the peptides, compositions, vaccines, or antibodies and methods for tailoring vaccines. -+ ~CD Number of Isolate tQ20.7 % emm"""""""" ,. .J 00D 08.3 % emm2 C1 4.1% emm4 0 3.7% emm8' CD 2.8% emm77/271 CD C-CD 2.5% emm2 CD 2.2% emm4 1.8% emm3 1.7% emm5 1.6% emm2 1.5% emm1 1.2% emm5

Patent Agency Ranking